2016 Access DEA History 
NORML
OCTOBER 21, 2019
Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.
WeedAdvisor
AUGUST 28, 2019
The applications were submitted as far back as 2016. Despite a 90-day deadline for review, the DEA ignored this cut-off and simply sat on the applications for three years. This likely would have been longer, but the DEA had not anticipated a legal threat to force some action. Dozens of Applications”. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SMPL
AUGUST 14, 2019
That includes a lack of access to financial services that lead such companies to operate on a largely cash basis, making them targets for crime. A report attached to the measure provides context on state-level legalization efforts, the history of federal prohibition and the “resulting regulatory quagmire.”.
Cannabis Law Report
JULY 9, 2021
Right to Try laws permit patients with serious or life-threatening diseases to access drugs that do not yet have government approval. Drug Enforcement Agency (“DEA”). Briefing is still under way, with the DEA’s responsive brief submitted on June 25, 2021, and the petitioners’ reply due July 16, 2021. AIMS Institute, PLLC.
Cannabis Law Report
NOVEMBER 2, 2021
The investigation covered a lot of important ground, but the main results concern the levels of delta-9 THC in each product, the inaccuracy of the labeling, how easily minors can get access to products and whether companies test for impurities. The second argument is based on a DEA interim final rule on the topic of synthetic THC.
Cannabis Law Report
SEPTEMBER 23, 2019
Cannabis use, both medically and recreationally, is prevalent throughout history. Surveying marijuana use is essential to gauge public health implications of increased access to marijuana, cannabinoid, and cannabis products. Background. Extensive evidence. 1 In the U.S. and 2.3%, respectively. and 2.3%, respectively.
Cannabis Law Report
APRIL 8, 2022
To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. Lyle Craker, Ph.D., Reddit awarded $82,765.95
Expert insights. Personalized for you.
103 
Let's personalize your content